TherapeuticsMD (TXMD) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
TherapeuticsMD Announces First Quarter 2018 Financial Results
May 3, 2018 4:05 PM EDT- $200 Million Non-Dilutive Term Loan Financing Completed to Support Commercialization -
- PDUFA target action date of May 29, 2018 for TX-004HR -
- PDUFA target action date of October 28, 2018 for TX-001HR -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced its financial results for the quarter ended March 31, 2018.
First Quarter and Recent Developments
Entered into a definitive loan agreement with MidCap Financial,... More